LinkedIn Share

Mabion Enters the Japanese Pharmaceutical Market


  • Japanese Pharmaceutical Market offers significant opportunities for advanced biologics and cost-effective biosimilars. Rapidly aging population driving growing demand for innovative therapies for chronic diseases.
  • Mabion’s visit to Japan marked a major milestone in our international expansion. Building on our established relationship with Japanese investor CBC Co., Ltd., we returned from Japan with valuable new business connections, promising opportunities for future collaboration and a stronger foundation for long-term partnerships connecting Polish expertise with Japanese pharmaceutical innovation.

BioJapan 2026: a Melting Pot of Innovation

Mabion team discuss with the partner during BioJapan 2026

From October 5 to 9, we participated in the EU-Japan Business Mission. The Polish Investment and Trade Agency facilitated the connection of Polish and Japanese companies from the biotechnology, pharmaceutical, and healthcare sectors. A key meeting with industry representatives was the BioJapan conference at PACIFICO Yokohama. This is one of the leading partnership events for the biotechnology industry in Asia. It took place from October 7 to 9, and our team represented the country in the Polish pavilion. More than 22,000 people attended this year’s trade show. BioJapan 2026 provided an excellent platform to introduce our capabilities to Japanese pharmaceutical and biotechnology companies seeking technically experienced and flexible development partners. We see BioJapan as the beginning of a broader dialogue on how Japanese scientific innovation and Polish biotechnology expertise can accelerate the development of promising treatments for patients across Asia and beyond.

Japan’s demographic transformation is creating one of the world’s most important healthcare challenges, with nearly 30% of its population now aged 65 or older. At BioJapan 2026, we had the opportunity to highlight how innovative biologics can help address the growing need for effective treatments in oncology, immunology and chronic diseases. Mabion brings together expertise in cell line development, advanced analytics, process optimization and GMP manufacturing, supporting biotechnology companies from early development through commercial production.

BioJapan 2026 represented another important step in executing Mabion’s 2025–2030 strategy and expanding our international business development activities. Our presence in Yokohama followed a broader programme of engagement with the Japanese market, reflecting our commitment to building relationships that extend beyond individual business meetings. The discussions reinforced our belief that European biologics development and manufacturing capabilities can play a valuable role in supporting Japanese biotechnology and pharmaceutical companies. With our established experience in biological medicines, growing focus on co-development and continued investment in our technological capabilities, Mabion is positioning itself to capture opportunities across international markets.

Gregor Kawaletz, Chief Executive Officer of Mabion

Japan is the world’s third-largest pharmaceutical market, valued at approximately $87 billion in 2025. We see significant potential to complement Japanese innovation with flexible European manufacturing capabilities, helping partners manage development risks and establish reliable supply strategies. Our participation in Yokohama marks an important step toward building lasting relationships with Japanese companies and contributing to the development of biological therapies that meet the needs of an aging society.

Mabion’s Business Mission Through Japanese Pharmaceutical Market

BioJapan wasn’t the only event our delegation attended. We took advantage of the business mission to participate in a EU-Japan Biotech & Pharma Partnering Conference in Osaka and a Business Seminar at the Polish Embassy in Tokyo. During the conference, Paulina Pobiedzińska, Analytics Development Division Manager, presented a research poster titled “Tailored by Design: Rethinking the Path to Biosimilar Development”, which describes our tailored clinical approach. Meanwhile, at the Polish Embassy, our CEO, Gregor Kawaletz, took the stage to present the strategic roadmap for Mabion’s global operations. We believe that our connections with the Japanese market are strong enough to blossom into a long-term partnership. We would like to express our sincere thanks to the Polish Investment and Trade Agency for organizing a joint business mission for companies in our sector.

I am pleased with the progress we are making in delivering Mabion’s strategy to strengthen our presence in the Asian market. Three cities, three events, one clear goal: to build a strong foundation for long-term partnerships and sustainable growth.

Our partnership with CBC Co., Ltd. is an important milestone in this journey. Our joint participation in the business seminar at the Polish Embassy in Tokyo and meeting during BioJapan reflects a shared commitment to strengthening business ties between Poland and Japan, with the support of both the business community and public institutions.

At Mabion, our ambition goes beyond providing services. We aim to be a trusted, long-term business partner, combining expertise and capabilities to advance the development and manufacturing of biological medicines. By building lasting partnerships between Europe and Asia, we want to create value not only for our business and the Polish biotechnology sector, but also for patients in both markets by helping bring innovative treatments closer to those who need them.

Our goal is clear: to turn international cooperation into lasting partnerships, meaningful business opportunities, and better solutions for patients.

Paweł Pobiedziński, Director of Business Development at Mabion

Prepared by:

Jakub Knurek
Jakub Knurek

Marketing Specialist

j.knurek@mabion.eu